By the end of this webinar, participants will be able to:

• Use bone remodeling marker, CTX to help decide whether to treat and to monitor treatment.
• Three antiresorptives - Actonel (risedronate), Zoledronic acid (Aclasta) and denosumab (prolia) reduce all three classes of fracture – spine, hip and non-vertebral fractures and do so safely.
• Adverse events of osteonecrosis of the jaw and atypical fractures are very uncommon events.
• Treatment in general is life-long. Consult before stopping therapy and if stopping, monitor to determine if bone loss recurs.
   

Our speakers:

• Professor Ego Seeman, Endocrinologist at the department of Medicine and Endocrinology, Austin Health, and University of Melbourne